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Clec16a has been identified as a disease susceptibil-
ity gene for type 1 diabetes, multiple sclerosis, and
adrenal dysfunction, but its function is unknown.
Here we report that Clec16a is a membrane-associ-
ated endosomal protein that interacts with E3 ubiqui-
tin ligase Nrdp1. Loss of Clec16a leads to an increase
in the Nrdp1 target Parkin, a master regulator of
mitophagy. Islets from mice with pancreas-specific
deletion of Clec16a have abnormal mitochondria
with reduced oxygen consumption and ATP concen-
tration, both of which are required for normal b cell
function. Indeed, pancreatic Clec16a is required for
normal glucose-stimulated insulin release. More-
over, patients harboring a diabetogenic SNP in the
Clec16a gene have reduced islet Clec16a expression
and reduced insulin secretion. Thus, Clec16a con-
trolsb cell function and prevents diabetes by control-
ling mitophagy. This pathway could be targeted for
prevention and control of diabetes and may extend
to the pathogenesis of other Clec16a- and Parkin-
associated diseases.
INTRODUCTION
Genome-wide association studies (GWASs) are a powerful
approach to the identification of genes involved in common hu-
man diseases yet are limited by the identification of variants in
the loci of genes with completely unknown functions. Further,
many SNPs identified in GWAS are found in intergenic regions
that affect the function of transcriptional enhancers located far
from the disease-relevant gene. Thus, it is critical to directlyexamine the functional role of potential disease genes and to
correlate gene variation in potential enhancers to expression of
the putative associated gene. Molecular understanding of new
disease loci may provide important insights into the pathogen-
esis of human diseases and reveal new therapeutic targets
(Pociot et al., 2010).
C-type lectin domain family 16, member A (Clec16a;
KIAA0350), a gene locus associatedwith type 1 diabetesmellitus
(T1DM), multiple sclerosis, and adrenal dysfunction (Hakonarson
et al., 2007; IMSGC, 2009; Skinningsrud et al., 2008; WTCCC,
2007), is a 24-exon gene that encodes a large protein (1,053
amino acids) with evolutionary conservation of the N terminus
but no recognizable conservedmotifs. Little is knownofmamma-
lian Clec16a function or of its role in disease pathogenesis.
Here we discover a key role for Clec16a in the regulation of
mitophagy, a selective form of autophagy necessary for mito-
chondrial quality control (Ashrafi and Schwarz, 2013). Utilizing
proteomics analyses, we determine that the E3 ubiquitin ligase
Neuregulin receptor degradation protein 1 (Nrdp1 or RNF41) in-
teracts with Clec16a and mediates Clec16a functions, through
the Nrdp1 target Parkin, in multiple cell types. We find a key
role for Clec16a in the maintenance of glucose homeostasis
through its effect on the mitochondrial health of pancreatic b
cells and, consequently, glucose-stimulated insulin secretion.
Lastly, we demonstrate that a diabetogenic SNP in the CLEC16A
locus correlates with islet CLEC16A expression, b cell function,
and glycemic control in human subjects.
RESULTS
Identification of E3 Ubiquitin Ligase Nrdp1 as a Specific
Partner of Clec16a
Wehypothesized that Clec16a plays an important role inmultiple
tissues and that the identification of novel Clec16a-interacting
partners might shed light on its function. To this end, we utilizedCell 157, 1577–1590, June 19, 2014 ª2014 Elsevier Inc. 1577
Figure 1. I-DIRT Identifies Clec16a Interaction with E3 Ubiquitin Ligase Nrdp1
(A) Representative western blot (WB) of parental NIH 3T3 fibroblast (12C6-labeled) or stably expressing Flag-Clec16a NIH 3T3 fibroblast (
13C6-labeled) input
protein lysates, supernatant, and Flag immunoprecipitation for Flag-Clec16a (n = 6).
(legend continued on next page)
1578 Cell 157, 1577–1590, June 19, 2014 ª2014 Elsevier Inc.
the I-DIRT (Isotopic Differentiation of Interactions as Random or
Targeted) technique (Tackett et al., 2005) to identify specific
Clec16a partners in NIH 3T3 fibroblasts stably expressing an
epitope-tagged form of Clec16a (Flag-Clec16a). NIH 3T3 fibro-
blasts containing Flag-tagged Clec16a were grown in heavy
isotopic abundance medium (13C6,
15N2-lysine and
13C6,
15N4-
arginine), whereas wild-type (WT) cells were grown in light
(12C, 14N), natural isotope abundance medium. Equal quantities
of the two cell preparations were mixed, and the epitope-tagged
protein complex was isolated (Figure 1A). With I-DIRT, specific
protein interactions are identified by mass spectrometry (MS)
as isotopically heavy, whereas nonspecific interactions appear
as amixture of isotopically light andheavy. Following immunoiso-
lation, we verified enrichment of Clec16a peptides by tandem
MS (Figure 1B). Of over 800 proteins that were isolated and
sequenced by MS, the I-DIRT approach identified the E3 ubiqui-
tin ligase Nrdp1 as the major specific partner of Clec16a
(Figure 1C). Tandem MS data confirmed enrichment of Nrdp1
peptides (Figure 1D). Broad coverage of the Nrdp1 protein
sequence was observed with MS identification of nine unique
Nrdp1 peptides from six independent I-DIRT experiments
(Figure 1E). We then validated the interaction of Clec16a and
Nrdp1 by coimmunoprecipitation with either Flag- or Nrdp1-
specific antisera and confirmed pull-down of the Clec16a-
Nrdp1 protein complex (Figure 1F).
Clec16a Regulation of the Nrdp1/Parkin Pathway
Our observation of Clec16a and Nrdp1 interaction led us to use
a loss-of-function approach to assess the role of Clec16a in the
regulation of pathways downstream of Nrdp1. We generated
mice with loxP sites flanking exon 3 of the Clec16a gene (Cle-
c16aloxP) and intercrossed them with UBC-Cre/ERT2 mice (Fig-
ure 2A). Primary dermal fibroblasts were isolated from
Clec16aloxP/loxP;UBC-Cre/ERT2 mice and WT littermates. After
treatment with hydroxytamoxifen (OHT), efficient recombination
at the Clec16a locus in OHT-treated Clec16aloxP/loxP;UBC-Cre/
ERT2 (Clec16aflox) fibroblasts was confirmed (Figure 2B). As an
E3 ligase, Nrdp1 will self-ubiquitinate to regulate its own stability
in part through interaction with deubiquitination enzymes (Wu
et al., 2004). We observed a reduction in Nrdp1 in Clec16aflox
fibroblasts compared to controls, and treatment with the protea-
some inhibitor MG132 normalized expression between the
groups (Figure 2C), suggesting that Clec16a protects Nrdp1
from proteosomal degradation.
Nrdp1 regulates proteosomal degradation of the E3 ligase
Parkin (Zhong et al., 2005), a key regulator of mitochondrial auto-
phagy or mitophagy (Jin and Youle, 2012). The initiation of mi-
tophagy is mediated by Parkin translocation to themitochondrial
outer membrane, allowing recognition of its outer membrane
substrates. At the mitochondrial surface, Parkin ubiquitinates(B) MS/MSmapmarked with b ions (blue) and y ions (red) for Clec16a-specific pep
in peptide sequence.
(C) I-DIRT ratios for > 800 proteins identified from six independent I-DIRT expe
indicated. Contaminant peptides (human keratin [K], immunoglobulins [Ig], tryps
(D) MS/MS map marked with b ions (blue) and y ions (red) for an Nrdp1-specific
(E) Amino acid sequence of Nrdp1 with peptides identified by MS (highlighted re
(F) Representative WB (three independent experiments) of lysates of Flag-Clec1mitofusins 1 and 2 and porin (Gegg et al., 2010; Geisler et al.,
2010), thereby promoting their degradation. Finally, rapid turn-
over of Parkin-bound mitochondria occurs through the auto-
phagosomal machinery (Jin and Youle, 2012). Following loss
of Clec16a, we observed a significant increase in Parkin expres-
sion (Figure 2D). As expected, Parkin levels dropped following
FCCP stimulation of mitophagy in WT fibroblasts, whereas
the increased Parkin levels in Clec16aflox fibroblasts were not
reduced following FCCP treatment (Figure 2D). To determine
whether the increased basal expression of Parkin in Clec16aflox
fibroblasts augments early events of mitophagy, we evaluated
Parkin localization following cellular fractionation. As expected,
Parkin did not significantly localize to mitochondria in WT fibro-
blasts; however, in Clec16aflox fibroblasts, Parkin was found in
the mitochondrial fraction (Figure 2E). Importantly, mitofusin 2
(Mfn2) expression was reduced in Clec16aflox compared to WT
fibroblasts (Figure 2F), consistent with increased Parkin activity
in mitochondria.
Alterations in expression of Mfn2, which has been previously
implicated in control of mitochondrial metabolism (Liesa and
Shirihai, 2013; Zorzano et al., 2010), led us to assess mitochon-
drial respiration following Clec16a loss of function.Wemeasured
oxygen consumption in NIH 3T3 fibroblasts stably expressing
small hairpin RNA (shRNA) directed against Clec16a as well as
Clec16aflox fibroblasts and their respective controls. Following
confirmation of reduced Clec16a expression by two indepen-
dent shRNA sequences (Figure S1A available online), we found
that loss of Clec16a led to a reduced oxygen consumption rate
(OCR) in NIH 3T3 fibroblasts (Figure S1B). Similarly, we observed
reduced OCR in Clec16aflox fibroblasts (Figures 2G and 2H). De-
fects in OCR were not due to effects on glycolysis, as glycolytic
function reflected by the extracellular acidification rate (ECAR)
was unchanged between the groups (Figure S1C). Transient
overexpression of Nrdp1 partially rescued OCR in Clec16aflox
fibroblasts as well as shClec16a-treated NIH 3T3 cells (Figures
S1D, S1E, and 2G). A similar partial rescue of OCR was also
observed following transient small interfering RNA (siRNA)-medi-
ated loss of function of Parkin in Clec16aflox fibroblasts (Fig-
ure 2H). In primary fibroblasts, both Nrdp1 overexpression and
Parkin loss of function returned Mfn2 expression to similar levels
between the groups (Figures S1E and S1F). Taken together,
we find that Clec16a regulation of the Nrdp1/Parkin pathway re-
strains mitophagy and maintains normal mitochondrial oxygen
consumption.
Pancreas-Specific Clec16a Deficiency Impairs Glucose
Tolerance by Reducing b Cell Function
Although T1DM is an autoimmune disease, many T1DM-associ-
ated genes are expressed in pancreatic b cells, suggesting
functions directly in b cells that may contribute to diseasetide sequence with calculated m/z ratios. Heavy residue indicated in bold print
riments with calculated nonspecific value of 0.5. Clec16a and Nrdp1 peaks
in [T], and albumin [A]) indicated by peaks below nonspecific interactors.
peptide sequence with observed and calculated m/z ratios.
sidues). Trypsin cleavage sites demarcated in blue.
6a NIH 3T3 fibroblasts following anti-Flag IP (left) or anti-Nrdp1 IP (right).
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pathogenesis (Eizirik et al., 2009; Soleimanpour and Stoffers,
2013). We previously found that Clec16a is expressed in pancre-
atic islets and that its expression is reduced in Pdx1+/ islets
(Sachdeva et al., 2009). Moreover, although previous reports
suggest that Clec16a is a natural killer (NK) cell-enriched factor
(Hakonarson et al., 2007), we observed that Clec16a is ubiqui-
tously expressed and at similar levels in pancreatic islets and
NK cells (Figure S2).
These observations led us to interrogate the role of Clec16a in
pancreatic b cell function in vivo. We generated pancreas-spe-
cific deletion of Clec16a (Clec16aloxP/loxP; Pdx1-Cre, hereafter
referred to as Clec16aDpanc). Clec16aloxP mice have normal
glucose tolerance and body weight prior to Cre-mediated
recombination (Figures S3A and S3B). Pdx1-Cre mice display
efficient Cre-mediated recombination within pancreatic islets,
mosaic recombination in the exocrine pancreas (Herrera,
2000), and little to no recombination within the hypothalamus
when crossed to a Rosa-LacZ reporter (A.V. Rozo and D.A.S.,
unpublished data). Pdx1-Cre mice did not exhibit glucose intol-
erance compared to WT controls (data not shown).
Clec16aDpanc mice exhibited a 70% reduction in islet
Clec16a transcript (Figure 3A), which correlated with reduced
islet Clec16a protein expression (Figures 3B and S3C). Clec16a
was expressed throughout the islet, including in b cells, with effi-
cient deletion in Clec16aDpanc islets (Figure 3C). Intraperitoneal
glucose tolerance testing (IPGTT) revealed that Clec16aDpanc
mice are significantly hyperglycemic compared to littermate
controls (p < 0.005 by ANOVA; Figure 3D). Further, Clec16aDpanc
mice have reduced basal and blunted insulin release at 0 and
3 min after glucose administration in vivo (Figure 3E) and in iso-
lated islets (Figure 3F), indicating decreased pancreatic islet
glucose-stimulated insulin release as the cause of the impaired
glucose tolerance in vivo. There were no differences in peripheral
insulin sensitivity between the groups (Figure S3D) and no evi-
dence of exocrine pancreatic dysfunction, such as weight loss
(Figure S3E), steatorrhea, or histologic abnormalities of acinar
or ductal cells in Clec16aDpanc mice.
Given the association of Clec16a with T1DM, we assessed
whether Clec16a deficiency was associated with immune infil-
tration and insulitis but found no evidence of infiltrating lympho-
cytes into the pancreatic islets of WT or Clec16aDpanc mice
(Figure S3E). Immunofluorescence for insulin and glucagon
revealed normal islet architecture in Clec16aDpanc mice (Fig-
ure S3F). b cell mass was also normal following Clec16a loss
of function (Figure S3G). The presence of normal islet architec-Figure 2. Clec16a Controls Mitochondrial Function through the Nrdp1
(A) Model of Cre-mediated recombination of the Clec16a locus.
(B) Clec16a expression by quantitative RT-PCR (qRT-PCR) of RNA isolated from
(C) Nrdp1 protein expression by WB of WT or Clec16aflox fibroblasts following ov
(D) Parkin expression by WB in WT or Clec16aflox fibroblasts following 3 hr treatm
(E) Parkin subcellular localization by WB in WT or Clec16aflox fibroblasts following
and actin serve as mitochondrial and cytosolic loading controls, respectively (n =
(F) Mfn2 expression by WB in WT or Clec16aflox fibroblasts following 3 hr treatm
(G) Fold OCR in WT or Clec16aflox fibroblasts, 96 hr after transient overexpressio
(H) Fold OCR in WT or Clec16aflox fibroblasts, 96 hr after transient transfection o
For all WBs, representative images chosen from among three independent experi
all three independent experiments. qRT-PCR and OCR data expressed as mean
also Figure S1.ture and b cell mass in the context of an increase in pancreatic
insulin content (Figure S3G) indicates that a functional defect
imposed by Clec16a deficiency accounts for the reduced insulin
release observed in vivo. This is supported by observations
in Min6 b cells following transient reduction of Clec16a expres-
sion by siRNA, which resulted in reduced glucose-stimulated
insulin release (Figures S4A and S4B). Normal insulin release
following depolarization with KCl in Clec16a-deficient Min6 b
cells (Figure S4B) suggests that Clec16a does not regulate
exocytosis.
Examination of b cells from Clec16aDpanc and littermate con-
trol mice by transmission electron microscopy (TEM) revealed
a dramatic impact on b cell ultrastructure. Although b cells
from both groups had the expected appearance of electron-
dense insulin granules, Clec16aDpanc b cells displayed an accu-
mulation of vacuolated structures, some containing partially
degraded cytoplasmic material consistent with autophagic
vacuoles, that were not seen in WT b cells (Figure 3G). Further,
Clec16aDpanc b cells displayed rounded mitochondria with
dramatically disordered and amorphous structure (Figures 3G
and 3H). These effects were also observed in Clec16aDpanc
a cells (data not shown).
Clec16a Deficiency Promotes the Accumulation of
Unhealthy Mitochondria
Mitochondrial function is a key regulator of glucose-stimulated
insulin release (Supale et al., 2012). The appearance of defects
in glucose tolerance, insulin secretion, and mitochondrial ultra-
structure in Clec16aDpanc b cells suggests that, similar to the
observations in primary fibroblasts, mitochondrial respiration is
impacted in Clec16aDpanc b cells. Indeed, islets isolated from
Clec16aDpanc mice displayed reduced glucose-stimulated OCR
as well as maximal OCR following FCCP treatment when
compared to WT islets (Figure 4A), with similar results in si-
Clec16a-treated Min6 b cells (Figure 4B). Accordingly, ATP level
was reduced following glucose stimulation of siClec16a-treated
Min6 b cells (Figure 4C).
Interestingly, mtDNA levels as well as levels of the mito-
chondrial proteins succinate dehydrogenase A (SDHA) and
mitochondrial complex IV subunit I (mtCOI) were increased in
Clec16aDpanc islets (Figures 4D and 4E), indicating an increase
in mitochondrial mass. Elevated mitochondrial content could
arise through increases in mitochondrial biogenesis or dimin-
ished degradation. We measured mRNA expression of PGC1a,
NRF1, and TFAM (Scarpulla, 2011) and found that they were/Parkin Pathway
vehicle (EtOH) or OHT-treated WT or Clec16aflox fibroblasts (n = 3/group).
ernight treatment with vehicle (DMSO) or 10 mM MG132 (n = 3/group).
ent with vehicle (DMSO) or 10 mM FCCP (n = 3/group).
cell fractionation and enrichment of mitochondrial or cytosolic proteins. SDHA
3/group). Fold mitochondrial parkin as estimated by densitometry.
ent with vehicle (DMSO) or 10 mM FCCP (n = 3/group).
n of empty vector (pcDNA3-33HA) or 33HA-Nrdp1 (n = 3/group).
f nontargeting (siNT) or Parkin (siParkin) siRNA (n = 3/group).
ments. Densitometry, shown adjacent to eachWB, represents mean (±SEM) of
(±SEM) of three experiments performed in triplicate. *p < 0.05; **p < 0.01. See
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Figure 3. Pancreas-Specific Clec16a Loss of Function Leads to Hyperglycemia due to Functional Defects in b Cells
(A) Clec16a mRNA expression by qRT-PCR from RNA isolated from WT or Clec16aDpanc islets (n = 10/group).
(B) Clec16a expression by WB in WT or Clec16aDpanc islets (n = 4/group).
(C) Immunohistochemistry of adjacent sections of WT and Clec16aDpanc pancreata for Clec16a (top) and insulin (bottom). Image shown is representative of IHC
performed in three mice/group.
(D) Blood glucose concentrations measured during IPGTT of 5-week-old WT and Clec16aDpanc littermates. p < 0.005 by ANOVA; n = 6–15/group.
(legend continued on next page)
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Figure 4. Clec16a Loss of Function Results
in the Accumulation of Unhealthy Mito-
chondria
(A) Relative OCR measured in isolated WT and
Clec16aDpanc islets (n = 6/group).
(B) OCR (n = 4/group) measured at baseline
or following 300 nM FCCP in Min6 b cells after
transfection with nontargeting (siNT) or Clec16a-
specific siRNA (siClec16a).
(C) Fold ATP concentrations (normalized to protein
content; n = 3/group) in Min6 b cells following
transfection with siNT or siClec16a.
(D) Relative mtDNA content measured by qPCR
(normalized to nuclear DNA expression) in isolated
WT and Clec16aDpanc islets (n = 3–4/group).
(E) Expression of the mitochondrial proteins
SDHA and mitochondrial complex IV subunit I
(mtCOI) in isolated WT and Clec16aDpanc islets
by WB.
(F) qRT-PCR of markers of mitochondrial biogen-
esis (PGC1a, NRF1, TFAM) and ROS-induced
genes (ND6 and NF-E2) from RNA isolated from
WT and Clec16aDpanc islets (n = 5/group).
For all WBs, representative images chosen from
three independent experiments performed. WB
densitometry represents mean (±SEM) of three
independent experiments. *p < 0.05; **p < 0.01.
See also Figures S5 and S6.not increased in Clec16aDpanc islets (Figure 4F), suggesting
that increased mitochondrial biogenesis does not contribute
to increased mitochondrial mass. The dramatic reduction in
PGC1a could reflect compensation for mitochondrial accumula-
tion in Clec16aDpanc islets. We also assessed expression of fac-
tors induced by reactive oxygen species, a potential regulator of
mitochondrial biogenesis, and observed no differences between
the groups (Figure 4F).(E) Serum insulin (n = 6–15/group) measured during in vivo glucose-stimulated insulin release testing in 8-w
(F) Fold glucose-stimulated insulin secretion following static incubations in 2.8 mM and 16.7 mM glucose
8-week-old littermates (n = 4/group).
(G) TEM images from 3-month-old WT and Clec16aDpanc b cells. Inset (lower right)—focused area of mitoch
(H) Quantification of changes in mitochondrial morphology (% of total mitochondria) observed in WT and Clec
mitochondria scored/animal).
Images captured from 3–6 animals/group. Representative WBs chosen from among four independent exper
represents mean (±SEM) of four independent experiments. *p < 0.05; **p < 0.01. See also Figures S2, S3, a
Cell 157, 1577–159To examine islet mitochondrial quality
control, we assessed the Nrdp1/Par-
kin pathway and found that, similar to
Clec16aflox fibroblasts, Nrdp1 expression
is reduced in Clec16aDpanc islets (Fig-
ure 5A). We also observed increased
Parkin levels (Figure 5B) associated with
decreased expression of Parkin tar-
gets Mfn2 and porin (Figure 5C). Nrdp1
and Parkin transcript levels were unaf-
fected (data not shown). The accumula-
tion of unhealthy mitochondria, coupled
with dysregulation of the Nrdp1/Parkin
pathway, implicates defective mitoph-agy/autophagy leading to impaired glucose-stimulated OCR
and insulin secretion in Clec16aDpanc mice.
The Clec16a/Nrdp1 Pathway Regulates
Autophagosome-Lysosome Fusion during Late
Mitophagy
A role for Clec16a in autophagosomal trafficking is supported by
the observation of autophagic vacuoles in Clec16aDpanc isletseek-old WT and Clec16aDpanc littermates.
performed in isolated WT or Clec16aDpanc islets of
ondria on EM images.
16aDpanc b cells in TEM images (250 independent
iments. Densitometry, shown adjacent to each WB,
nd S4.
0, June 19, 2014 ª2014 Elsevier Inc. 1583
Figure 5. Clec16a Regulates Mitophagy
(A) Nrdp1 expression by WB of WT and Clec16aDpanc islets. Representative WB chosen from four independent experiments performed. Each sample analyzed
comprised islet lysates pooled from eight mice (32 mice total/group).
(B) Parkin expression by WB of WT and Clec16aDpanc islets following 3 hr of vehicle (DMSO) or 10 mM FCCP (n=3/group). Black lines between vehicle and FCCP-
treated islet WBs used to denote samples that were run on separate gels.
(legend continued on next page)
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(Figure 3G) and of reduced Mfn2 in Clec16aflox fibroblasts and
Clec16aDpanc islets. Defective autophagosome-lysosome fusion
has been reported following depletion of Mfn2 in cardiomyo-
cytes (Zhao et al., 2012). To assess trafficking defects during
mitophagy, we used fluorescent-labeledmarkers for autophago-
somes (LC3-GFP) and mitochondria (mito-dsRed) in WT and
Clec16aflox fibroblasts to assess colocalization of autophago-
somes with mitochondria. We found increased LC3-GFP and
mito-dsRed colocalization in Clec16aflox fibroblasts (Figures 5D
and 5E), indicating that the autophagosomal machinery does
not efficiently degrade autophagosomes containing mitochon-
dria. As reduced autophagic flux could be a cause of mitochon-
drial accumulation in autophagosomes, we quantified LC3-GFP
puncta with and without Bafilomycin A1 (BafA1), an inhibitor of
the vacuolar H+ ATPase. As expected, LC3-GFP puncta accu-
mulated in WT fibroblasts following BafA1 exposure, but this
did not occur in Clec16aflox fibroblasts, suggesting a defect in
autophagic flux (Figures 5D and 5F). Lastly, following FCCP-
mediated depolarization to inducemitophagy, we found reduced
colocalization of LC3 with the lysosomal marker Lamp1 (Figures
5G and 5H), indicating a defect in trafficking of autophagosomes
to the lysosomal compartment during late mitophagy. Overex-
pression of Nrdp1 rescued the reduced colocalization of LC3/
Lamp1 seen in Clec16aflox fibroblasts (Figure 5I), indicating
that Clec16a regulation of autophagosomal trafficking is medi-
ated at least in part by Nrdp1. Taken altogether, the Clec16a/
Nrdp1 pathway modulates mitochondrial function through regu-
lation of mitophagy/autophagy.
Reduced mitochondrial function due to Clec16a deficiency
mediated by increased Parkin expression contrasts with previ-
ously reported beneficial effects of Parkin overexpression on life-
span and cell viability (Rana et al., 2013; Suen et al., 2010).
We hypothesized that the simultaneous defect in clearance of
unhealthy mitochondria caused by the defect in autophagoso-
mal-lysosomal trafficking explains this unexpected result. To
directly test this hypothesis, we overexpressed mCherry-Parkin
in Min6 b cells and then tested the importance of autophago-
some-lysosome fusion to mitochondrial oxygen consumption
utilizing two pharmacologic inhibitors of the vacuolar H+
ATPase (vATPase), the pleomacrolide Bafilomycin A1 and
KM91104, which disrupts a subunit of the vATPase highly ex-
pressed in pancreatic b cells (Kartner et al., 2010; Sun-Wada
et al., 2006). We observed the expected inhibition of acidification
of endolysosomal compartments by BafA1 and KM91104 (Fig-(C) Mfn2 and porin expression byWB inWT andClec16aDpanc islets following 3 hr
FCCP-treated islet WBs used to denote samples that were run on separate gels
(D) Representative deconvolution image of WT and Clec16aflox fibroblasts, 72 hr a
or 150 nM BafA1 for 6 hr.
(E) Quantification of LC3-GFP/mito-dsRed colocalization in WT and Clec16aflox fi
(F) Fold LC3-GFP puncta quantified from WT and Clec16aflox fibroblasts, 72 hr af
for 6 hr.
(G) Representative deconvolution image of WT and Clec16aflox fibroblasts treat
Lamp1 (green), LC3 (red), and DAPI (blue).
(H) Quantification of LC3+ Lamp1+ colocalization in WT and Clec16aflox fibroblas
(I) Quantification of LC3+ Lamp1+ colocalization in non-FCCP-treated WT and
(pcDNA3-33HA) or 33HA-Nrdp1 (n = 5–7/group).
For (B) and (C), representativeWBs chosen from three independent experiments p
of all experiments performed. *p < 0.05; **p < 0.01. See also Figures S5 and S6ure S5A). Due to the reported off-target effect of BafA1 to disrupt
mitochondrial function by acting as a K+ ionophore (Teplova
et al., 2007), we assessed respiration of isolated mitochondria
from Min6 b cells treated with both inhibitors. Although BafA1
did impair isolated mitochondrial function (Figure S5B; Veh
RCR 5.78 ± 0.60, BafA1 RCR 3.00 ± 0.22, p < 0.01), KM91104
did not, allowing us to use this inhibitor to selectively assess
the role of endolysosomal function on whole-cell respiration
(Figure S5B; Veh RCR 4.40 ± 0.36, KM91104 RCR 3.75 ± 0.31,
p = 0.27). As expected, Parkin overexpression reduced porin
expression, indicative of functional overexpression (Figure S5C).
Although overexpression of Parkin or KM91104 treatment alone
did not cause marked reductions in oxygen consumption,
the addition of vATPase inhibition to Parkin overexpression
dramatically reduced oxygen consumption (Figure S5D).
Echoing our findings with Clec16a loss of function, we conclude
that increased early mitophagy by overexpressed Parkin in addi-
tion to impaired autophagosomal trafficking in late mitophagy
together are necessary to cause deleterious effects on mito-
chondrial function in pancreatic b cells.
Pancreas-Specific Clec16a Deficiency Induces Age-
Dependent b Cell ER Stress
The effect of Clec16a on expression of Parkin and Mfn2 sug-
gests that Clec16a could affect other Mfn2-regulated pathways.
Beyond regulation of mitochondrial respiration and dynamics,
Mfn2 regulates ER function and the unfolded protein response
by mediating an interaction between the ER and mitochondria
(de Brito and Scorrano, 2008; Ngoh et al., 2012). Further, Mfn2
plays a vital role in ER homeostasis in POMC neurons
(Schneeberger et al., 2013), a neuroendocrine secretory cell
with similarity to b cells. Notably, by EM, we observed an
accumulation of electron lucent vacuolated structures in Cle-
c16aDpanc b cells that was not observed in WT b cells (Figures
S6A and S6B). By 3D EM reconstruction tomography, we at-
tempted to determine the identity of these structures. Whereas
WT b cells possess normal stacks of ER seen throughout the
cytoplasm (Movie S1; Figure S6B), in Clec16aDpanc b cells, we
observed two distinct populations of electron lucent vacuolated
structures: large interconnected vacuoles, which likely represent
dilated ER (Movie S2; Figure S6C), as well as smaller
spherical vacuoles, which could represent endosomes (Movie
S3; Figure S6D). We also found increased levels of IRE1a
and spliced XBP1 in 6-month-old Clec16aDpanc isletsof vehicle (DMSO) or 10 mMFCCP (n=3/group). Black lines between vehicle and
.
fter overexpression of LC3-GFP and mito-dsRed, treated with vehicle (DMSO)
broblasts following vehicle (DMSO) or 150 nM BafA1 for 6 hr (n=5-8/group).
ter overexpression of LC3-GFP, treated with vehicle (DMSO) or 150 nM BafA1
ed with 10 mM FCCP for 60 min followed by indirect immunofluorescence for
ts following 10 mM FCCP for 60 min (n=5/group).
Clec16aflox fibroblasts, 72 hr after transient overexpression of empty vector
erformed. Densitometry, shown adjacent to eachWB, representsmean (±SEM)
and Movies S1, S2, and S3.
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(Figure S6E), consistent with ER stress. Interestingly, 6-week-
old Clec16aDpanc islets did not express increased levels of
sXBP1 (Figure S6E), suggesting the development of progressive
ER stress with age. In contrast, Clec16aflox fibroblasts did not
develop noticeably abnormal ER morphology, assessed by
confocal microscopy of the ER marker protein disulfide isom-
erase (PDI) (Figure S6F). We speculate that high secretory de-
mand promotes the development of ER stress in the context
of defects caused by Clec16a deficiency. These studies impli-
cate Clec16a as an upstream regulator of several pathways
downstream of Nrdp1, Parkin, and Mfn2, including ER function,
autophagy, and mitochondrial function.
Clec16a Is a Membrane-Associated Endolysosomal
Protein
Regulation of mitochondrial function by Clec16a led us to ask
whether Clec16a is a mitochondrial protein. The subcellular
localization of Clec16a has been in question, with recent studies
suggesting that Clec16a strictly localizes to endosomal, Golgi,
or ER compartments (Kim et al., 2010, 2012; Zouk et al.,
2013). We assessed Clec16a subcellular localization in Min6
b cells stably expressing Flag-Clec16a following biochemical
fractionation. Clec16a was not enriched in mitochondria
but rather was equally expressed in cytosolic and membrane
fractions (Figure S7A). Alkaline carbonate extraction displaced
Clec16a from the membrane fraction, indicating that Clec16a
is membrane associated (Figure S7B). Overlay of membrane
proteins on a noncontinuous Nycodenz gradient demonstrated
Clec16a enrichment in fractions similar to those of proteins
in the endolysosomal pathway (including Rab5, Rab7, and
Lamp1) and distinct from those of the ER, Golgi, and secretory
granules (Figure S7C). Similarly, we found Clec16a colocalized
with the lysosomal marker Lamp1 by immunostaining (Fig-
ure S7D). Thus, Clec16a is a membrane-associated endolyso-
somal protein.
Localization of Clec16a to the endosomal compartment and
the accumulation of small vacuoles on EM (Figure S6D) led
us to examine endosomal trafficking of Clec16a-deficient
pancreatic b cells. We estimated endosomal trafficking utilizing
fluid-phase tracers in both dispersed pancreatic islets plated in
monolayers and Min6 b cells. Following pulse-chase of horse-
radish peroxidase (HRP), 5.7% of HRP remained in WT islets.
In contrast, Clec16aDpanc islets could not degrade HRP as
effectively, with 23.4% of HRP remaining after a 180 min chase
(Figures 6A and 6B). In a complementary approach, we also
utilized fluorescent-conjugated dextran tracers to estimate
endolysosomal trafficking (Figures 6C and S7E) and found a
reduction in FITC- and TRITC-dextran colocalization over time
in siClec16a Min6 cells (p < 0.05 by ANOVA; Figures 6D and
6E), indicating impaired endosomal trafficking. We noted no
significant differences in total labeled-dextran uptake, ruling
out a defect in endocytosis (Figure S7F). Rab7 immunoreac-
tivity was also increased, suggesting an accumulation of late
endosomes following Clec16a loss of function (Figure 6F). Inter-
estingly, overexpression of Nrdp1 reduced the accumulation of
HRP in Clec16aflox fibroblasts, indicating that Nrdp1 mediates
the effect of Clec16a on endosomal trafficking (Figure 6G).
Therefore, the endolysosomal protein Clec16a is a mediator1586 Cell 157, 1577–1590, June 19, 2014 ª2014 Elsevier Inc.of both endosomal and autophagosomal trafficking in part
through Nrdp1.
ADiabetogenic CLEC16A SNPAssociatedwith Reduced
Islet CLEC16A Expression and b Cell Function in
Humans
To determine whether CLEC16A regulates human pancreatic b
cell function and potentially contributes to disease pathogenesis
in humans, we studied the impact of diabetogenic CLEC16A
SNP rs12708716 (Hakonarson et al., 2007; Todd et al., 2007;
WTCCC, 2007) on islet CLEC16A expression, b cell function,
and glucose homeostasis. We assessed complementary
high-throughput DNA sequencing and RNA sequencing data
from > 80 healthy human islet donors. In islet donors possessing
one or two copies of the T1DM-associated SNP, we observed
a dose-dependent decrease of CLEC16A mRNA expression
(Figure 7A), indicating that rs12708716 acts as an expression
quantitative trait locus for CLEC16A. Then, we accessed data
collected by the Meta-Analyses of Glucose and Insulin-related
traits Consortium (MAGIC) to correlate rs12708716 with b cell
function as measured by HOMA-b (Dupuis et al., 2010).
Following adjustment for age, sex, study covariates, as well as
natural log transformation of HOMA-b data, rs12708716 reduced
HOMA-b measurements by 7.4 3 103 ± 3.4 3 103 (p < 0.03;
n = 35,285) while not impairing peripheral insulin sensitivity as
measured by HOMA-IR. Lastly, we found a small but significant
elevation in hemoglobin A1c in nondiabetic human islet donors
homozygous for the rs12708716 SNP (Figure 7B), thus linking
a T1DM-associated SNP to islet CLEC16A expression, b cell
function, and glucose homeostasis in humans.
DISCUSSION
Here we identify the diabetes susceptibility gene Clec16a as a
novel regulator of mitophagy through upstream regulation of
the Nrdp1/Parkin pathway. The E3 ubiquitin ligase Nrdp1 is a
major interacting partner of Clec16a, and Clec16a appears to
protect Nrdp1 from proteosomal degradation. The mechanism
by which Clec16a stabilizes Nrdp1 remains to be explored.
Nrdp1 is efficiently degraded by the ubiquitin-proteosome sys-
tem; mutations in the RING finger domain that disrupt its ubiqui-
tin ligase activity enhance Nrdp1 stability (Wu et al., 2004). Nrdp1
stability is also maintained by interaction with the deubiquitinat-
ing enzyme USP8 (Avvakumov et al., 2006; Wu et al., 2004).
Similar to Clec16a, USP8 controls endosomal trafficking as
well as endosomal ubiquitin dynamics and cell-surface receptor
turnover (Mizuno et al., 2005; Row et al., 2006). Our observations
regarding Clec16a localization, function, and interaction with
Nrdp1, along with the role of Drosophila ortholog Ema in
epidermal growth factor receptor (EGFR) stability (Kim et al.,
2010), suggest a tripartite regulation of membrane trafficking,
receptor ubiquitination and degradation, and mitophagy by
Clec16a, Nrdp1, and USP8.
We describe an important role for mitophagy in the regulation
of pancreatic b cell function via regulation of key proteins essen-
tial for both mitochondrial respiration and dynamics. It is well
known that pancreatic b cells rely heavily onmitochondrial respi-
ration to maintain normal glucose-stimulated insulin release.
Figure 6. Clec16a Regulates b Cell Endoso-
mal Trafficking
(A) Study design for HRP (5 mg/ml) trafficking and
degradation by a pulse-chase approach.
(B) Quantification of undegraded HRP activity
in dispersed WT and Clec16aDpanc islets (n = 6/
group).
(C) Study design for fluorescent-conjugated
dextran trafficking and colocalization by pulse-
chase in Min6 b cells.
(D) Quantification of FITC-dextran and TRITC-
dextran colocalization over time inMin6 b cells (p <
0.05 by ANOVA; n = 3/group) 72 hr after transient
transfection with nontargeting or Clec16a-specific
siRNA.
(E) Representative deconvolution image of FITC-
dextran- and TRITC-dextran-treated Min6 b cells
(3 hr post-TRITC-dextran chase) following tran-
sient transfection with nontargeting or Clec16a-
specific siRNA.
(F) Representative deconvolution image following
immunofluorescence staining for Rab7 (red) and
DAPI (DNA, blue) of Min6 b cells after transient
transfection with nontargeting or Clec16a-specific
siRNA.
(G) Quantification of undegraded HRP activity in
WT and Clec16aflox fibroblasts, 72 hr after over-
expression of empty vector (pcDNA3-33HA) or 3
3HA-Nrdp1, utilizing HRP pulse-chase approach
(n = 6/group).
*p < 0.05; **p < 0.01. See also Figure S7 and
Movies S1 and S3.Recent reports also demonstrate the importance of mitochon-
drial dynamics to b cell function (Stiles and Shirihai, 2012; Supale
et al., 2012). Dysfunctional mitophagy is known to lead to both
mitochondrial respiratory dysfunction and defects in mitochon-
drial dynamics (under the control of Mfn1 and Mfn2, which we
show to be targeted by the Clec16a/Nrdp1/Parkin pathway)
(Youle and Narendra, 2011).
Our observations of defective insulin release, impaired
glucose homeostasis, and ER stress related to b cell dysfunctionCell 157, 1577–159in the context of Clec16a deficiency may
provide insight into early non-immune-
related events in the course of T1DM.
Among the earliest signs of T1DM in
nondiabetic, high-risk patients is the
loss of first-phase insulin release (FPIR),
an early indicator of b cell impairment
(Chase et al., 2001; Defronzo, 2009),
with only rare instances of insulitis (In’t
Veld et al., 2007), suggesting that b cell
dysfunction predates insulitis. Similarly,
animal models of T1DM display loss
of FPIR and b cell ER stress prior to im-
mune infiltration (Ize-Ludlow et al., 2011;
Marhfour et al., 2012). ER stress in turn
may serve as a trigger for autoimmunity
(Tersey et al., 2012). The expression of60% of T1DM-associated genes in pancreatic islets further
supports that the b cell is more than an innocent bystander in
its own demise (Eizirik et al., 2012; Soleimanpour and Stoffers,
2013).
These studies demonstrate that Clec16a controls b cell func-
tion by regulating mitophagy/autophagy. Regulation of insulin
secretion by mitophagy has not been previously appreciated
in diabetes. The Clec16a/Nrdp1/Parkin axis in b cells could be
targeted to prevent or control T1DM and serve as a basis for0, June 19, 2014 ª2014 Elsevier Inc. 1587
Figure 7. The Diabetogenic CLEC16A SNP rs12708716 Is Associated
with Reduced Islet CLEC16A Expression and Impaired Glucose
Control
(A) Human islet CLEC16A RNA expression measured by RNA-seq in islet
donors stratified by DNA sequencing at position of rs12708716 A/G SNP.
**p < 0.001.
(B) Hemoglobin A1c measurements in islet donors sequenced at position
of rs12708716 A/G SNP.
For all graphs, data expressed as mean (±SEM, denoted in error bars). AA,
n = 31/group; AG, n = 42/group; GG, n = 8/group. *p < 0.05.understanding the pathogenesis of other Clec16a- and Parkin-
related diseases.
EXPERIMENTAL PROCEDURES
Please see the Extended Experimental Procedures for additional details.
Proteomics Studies
Stably expressing Flag-Clec16a or control NIH 3T3 fibroblasts were main-
tained for at least five doublings in DMEM not containing lysine or arginine
(Invitrogen) supplemented with 0.398 mM arginine and 0.798 mM lysine or
0.398 mMU-13C6,
15N4-arginine and 0.798 mMU-
13C6,
15N2-lysine (Cambridge
Isotope Laboratories). Cell lysis and immunoprecipitation were performed with
Anti-Flag M2 affinity gel (Sigma). Samples were run in a 10% Bis Tris reducing
gel (Invitrogen), stained with Coomassie blue, and pixilated as described
(Shevchenko et al., 1996). Tryptic digests were analyzed by liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) on a hybrid LTQ Orbitrap Elite
mass spectrometer (ThermoFisher) coupled with a nanoLC Ultra (Eksigent).1588 Cell 157, 1577–1590, June 19, 2014 ª2014 Elsevier Inc.Animals
Animal studies were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee. To generate Clec16aloxP mice, a 15.3 kb
C57BL/6 genomic DNA fragment containing exons 2–4 and flanking intronic
sequence was subcloned into plasmid FLSniper (Ozgene) containing an
FRT-flanked PGK-driven Neomycin cassette. LoxP sites flanked exon 3. The
linearized targeting vector was electroporated into B6 embryonic stem cells
(ESCs), and clones that survived selection were screened for homologous
recombination by Southern blot. Targeted clones were injected into C57BL/
6-derived blastocysts and transferred to pseudopregnant females. Male
offspring were mated to C57BL/6 females, and ESC-derived offspring were
identified by PCR-based genotyping. Mice harboring the targeted insertion
of the two loxP sites in the Clec16a gene locus were then crossed to the
ACTB-FLPe line to achieve deletion of the FRT-flanked Neomycin cassette
(Rodrı´guez et al., 2000). Clec16aloxP mice were mated to UBC-Cre/ERT2
mice (Ruzankina et al., 2007) or Pdx1-Cre (Herrera, 2000) to generate experi-
mental groups. All animals were maintained on a 100% C57BL/6 background.
Oxygen Consumption Assays
Oxygen consumption was measured in isolated islets by a Clark-type O2 elec-
trode (Strathkelvin Instruments) and in mitochondria or adherent cells using a
XF24 Flux Analyzer (Seahorse Bioscience).
Human Islet Studies
Islets from nondiabetic cadaver donors (n = 81) were provided by the Nordic
Islet Transplantation Program (http://www.nordicislets.org). Purity of islets
was assessed as described previously (Taneera et al., 2012). RNA-seq libraries
were prepared using the standard Illumina mRNA-Seq protocol, and
sequencing was performed on an Illumina HiSeq 2000. Gene expression was
considered as the normalized sum of expression of all exons, and further
normalization was applied by adjusting the expression to gene length as previ-
ously described (’t Hart et al., 2013). GWAS on DNA from islet donors was per-
formed using the Genome-Wide Human SNP array 6.0 containing 906,000
SNPs (Affymetrix) as described (Taneera et al., 2012). Hemoglobin A1c values
were measured in banked donor serum samples obtained prior to death.
Statistical Analysis
Data are presented as mean ± SEM, unless otherwise noted. Statistical com-
parisons were performed using the Student’s t test or two-way ANOVA (Prism
GraphPad). For 2 3 2 comparisons that reached statistical significance by
ANOVA (p < 0.05), a protected Fisher’s least significant difference test was
utilized for post-hoc analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and three movies and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.05.016.
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